Erik Swain

Editor's Note: After the June issue of Healio | Endocrine Today went to press, a U.S. district judge voided the H-1B visa fee discussed in this article.

CHICAGO — Most men who received testosterone therapy did not receive a workup in accordance with guidelines, and some received the treatment despite being contraindicated for it, researchers reported at ENDO 2026.

An update to the previously published multispeciality guide for the management of diabetes, cardiorenal and metabolic diseases will be issued later this year with sweeping updates based on the latest data, a speaker reported.

CHICAGO — An AI model using electronic health record data helped researchers narrow down who should be screened for primary aldosteronism, according to a poster presented at ENDO 2026.

CHICAGO — In patients with fibrodysplasia ossificans progressiva, an oral selective inhibitor of activin receptor–like kinase 2 was linked to lower odds of new heterotopic ossification lesions vs. placebo at 24 weeks, researchers reported. Interim results of the PROGRESS study, presented at ENDO 2026, included data from 63 patients aged 12 years or older with fibrodysplasia ossificans

CHICAGO — In a cohort of patients with difficult-to-control type 2 diabetes, approximately one-quarter had hypercortisolism, according to interim results of part 1 of the CAPTAIN-T2D study presented at ENDO 2026.

CHICAGO — Neurological and pancreatic complications are common in patients with congenital hyperinsulinism, according to a systematic review presented at ENDO 2026.

Khadijah Breathett, MD, MS, FACC, FAHA, FHFSA, and colleagues have been at the forefront of research on disparities in heart transplantation. The group’s most recent paper indicates that racial disparities in acceptance of a first offer of a donor heart may be tied to the decision-making process at the individual center level.

CHICAGO — Among patients with type 2 diabetes who discontinued use of a GLP-1 receptor agonist, more than half reinitiated within 1 year and about two-thirds reinitiated within 2 years, researchers reported at ENDO 2026. “The question we were asking is, of the patients who do go on GLP-1s, who have type 2 diabetes, how many of them actually stay on treatment?” Sanjeev Rampam, MD, resident

SCOTTSDALE, Ariz. — Large language models were not as good as dietitians at generating meal plans for patients with hypertension, according to